NASDAQ:CRBU Caribou Biosciences (CRBU) Stock Price, News & Analysis $1.30 -0.01 (-0.76%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$1.34 +0.03 (+2.69%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Caribou Biosciences Stock (NASDAQ:CRBU) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Caribou Biosciences alerts:Sign Up Key Stats Today's Range$1.30▼$1.3450-Day Range$1.25▼$1.8052-Week Range$1.25▼$3.54Volume1.84 million shsAverage Volume1.17 million shsMarket Capitalization$139.37 millionP/E RatioN/ADividend YieldN/APrice Target$7.75Consensus RatingModerate Buy Company Overview Caribou Biosciences, Inc. is a clinical-stage biotechnology company developing genome-edited cell therapies for the treatment of cancer. The company uses its CRISPR-based chRDNA™ technology platform to make targeted genetic modifications to immune cells, with the goal of creating more effective and scalable therapies. Caribou’s pipeline has focused primarily on allogeneic, or “off-the-shelf,” CAR-T cell therapies. Its investigational programs have included CB-010, an anti-CD19 CAR-T therapy designed for certain blood cancers, as well as additional programs targeting diseases such as multiple myeloma and acute myeloid leukemia. These therapies are intended to use donor-derived cells that are edited to improve their function and reduce the risk of immune rejection. Founded in 2011 and headquartered in Berkeley, California, Caribou was co-founded by Nobel Prize-winning scientist Jennifer Doudna. Rachel Haurwitz, Ph.D., has served as the company’s president and chief executive officer. Caribou conducts research and clinical development activities in the United States and collaborates with biotechnology and pharmaceutical organizations to advance its genome-editing platform and therapeutic candidates.AI Generated. May Contain Errors. Read More Caribou Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreCRBU MarketRank™: Caribou Biosciences scored higher than 42% of companies evaluated by MarketBeat, and ranked 606th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingCaribou Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCaribou Biosciences has a consensus price target of $7.75, representing about 496.2% upside from its current price of $1.30.Amount of Analyst CoverageCaribou Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Caribou Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Caribou Biosciences are expected to decrease in the coming year, from ($0.88) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Caribou Biosciences is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Caribou Biosciences is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCaribou Biosciences has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Caribou Biosciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.75% of the float of Caribou Biosciences has been sold short.Short Interest Ratio / Days to CoverCaribou Biosciences has a short interest ratio ("days to cover") of 12.94, which indicates bearish sentiment.Change versus previous monthShort interest in Caribou Biosciences has recently increased by 0.29%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCaribou Biosciences does not currently pay a dividend.Dividend GrowthCaribou Biosciences does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.14 News SentimentCaribou Biosciences has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Caribou Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for CRBU on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows4 people have added Caribou Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Caribou Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders8.54% of the stock of Caribou Biosciences is held by insiders.Percentage Held by Institutions77.51% of the stock of Caribou Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Caribou Biosciences' insider trading history. Receive CRBU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRBU Stock News HeadlinesCaribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from BrokeragesSeptember 19 at 2:44 AM | americanbankingnews.comCaribou Biosciences (NASDAQ:CRBU) Downgraded by Wall Street Zen to "Sell"September 19 at 1:30 AM | americanbankingnews.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.September 20 at 1:00 AM | Paradigm Press (Ad)Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Caribou Biosciences (CRBU) and Aveanna Healthcare Holdings (AVAH)August 15, 2026 | theglobeandmail.comCaribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 13, 2026 | globenewswire.comCaribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceJune 29, 2026 | globenewswire.comCaribou Biosciences Shareholders Decide Key Governance MattersJune 18, 2026 | tipranks.comCaribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026June 11, 2026 | globenewswire.comSee More Headlines CRBU Stock Analysis - Frequently Asked Questions How have CRBU shares performed this year? Caribou Biosciences' stock was trading at $1.59 on January 1st, 2026. Since then, CRBU stock has decreased by 18.2% and is now trading at $1.30. How were Caribou Biosciences' earnings last quarter? Caribou Biosciences, Inc. (NASDAQ:CRBU) posted its quarterly earnings data on Thursday, August, 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.08. The company had revenue of $1.50 million for the quarter, compared to analysts' expectations of $2.28 million. Caribou Biosciences had a negative net margin of 1,030.42% and a negative trailing twelve-month return on equity of 89.11%. When did Caribou Biosciences IPO? Caribou Biosciences (CRBU) raised $285 million in an IPO on Wednesday, July 21st 2021. The company issued 19,000,000 shares at a price of $14.00-$16.00 per share. Who are Caribou Biosciences' major shareholders? Caribou Biosciences' top institutional investors include BlackRock Inc. (7.88%), Bank of America Corp DE (1.42%), GSA Capital Partners LLP (0.47%) and Green Alpha Advisors LLC (0.37%). Insiders that own company stock include Rachel E Haurwitz, Barbara G Mcclung, Ruhi Ahmad Khan, Timothy P Kelly, Tina M Albertson and Sriram Ryali. View institutional ownership trends. How do I buy shares of Caribou Biosciences? Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Caribou Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Caribou Biosciences investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/13/2026Today9/20/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 3 weeks, CRBU's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRBU CIK1619856 Webcariboubio.com Phone510-982-6030FaxN/AEmployees97Year Founded2012Price Target and Rating Average Price Target for Caribou Biosciences$7.75 High Price Target$11.00 Low Price Target$5.00 Potential Upside/Downside+496.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$148.12 million Net Margins-1,030.42% Pretax Margin-1,035.90% Return on Equity-89.11% Return on Assets-62.47% Debt Debt-to-Equity RatioN/A Current Ratio6.49 Quick Ratio6.49 Sales & Book Value Annual Sales$11.16 million Price / Sales12.49 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book0.99Miscellaneous Outstanding Shares107,210,000Free Float98,052,000Market Cap$139.37 million OptionableOptionable Beta2.28 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CRBU) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredThe Last Gold Bull Market?Former CIA and Pentagon official Jim Rickards says the current gold bull market could be its last. Investment ...Paradigm Press | SponsoredNo Wallstreet. No Advisor. No Problem.Savings accounts pay just 0.58 percent interest. Andy Howard, co-founder of Meridian Capital, says liquidity p...Awesomely | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
